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Abstract
Background: BCG, the only licensed vaccine against tuberculosis, provides some protection against disseminated disease in
infants but has little effect on prevention of adult pulmonary disease. Newer parenteral immunization prime boost regimes
may provide improved protection in experimental animal models but are unproven in man so that there remains a need for
new and improved immunization strategies.
Methods and Findings: Mice were immunized parenterally, intranasally or simultaneously by both routes with BCG or
recombinant mycobacterial antigens plus appropriate adjuvants. They were challenged with Mycobacterium tuberculosis
(Mtb) and the kinetics of Mtb growth in the lungs measured. We show that simultaneous immunization (SIM) of mice by the
intranasal and parenteral routes is highly effective in increasing protection over parenteral BCG administration alone.
Intranasal immunization induces local pulmonary immunity capable of inhibiting the growth of Mtb in the early phase (the
first week) of infection, while parenteral immunization has a later effect on Mtb growth. Importantly, these two effects are
additive and do not depend on priming and boosting the immune response. The best SIM regimes reduce lung Mtb load by
up to 2 logs more than BCG given by either route alone.
Conclusions: These data establish SIM as a novel and highly effective immunization strategy for Mtb that could be carried
out at a single clinic visit. The efficacy of SIM does not depend on priming and boosting an immune response, but SIM is
complementary to prime boost strategies and might be combined with them.
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Introduction
Development of effective booster vaccines is hampered by lack
of understanding of protective immunity to tuberculosis or BCG-
induced protection [1]. In animals, parenteral immunization with
recombinant (rec) viruses containing Mtb genes generates powerful
immune responses, but has only weak or transient protective
effects. Nor have these vectors generally boosted protection
effectively when administered parenterally after BCG priming
[2–8]. Several adjuvanted rec Mtb proteins have shown protection
equal to BCG; however, after BCG priming the increase in
protection afforded by parenteral boosters is variable. The most
effective regimes require repeated administration of rec Mtb fusion
proteins [9–11], sometimes combined with further booster doses of
BCG [12]. In contrast, immunization via the respiratory tract is
frequently highly effective: both rec proteins and viral vectors
induce protective immunity and boost parenteral BCG-induced
protection [5,13–16]. Respiratory administration of spray dried
BCG is highly effective in guinea pigs [17].
Following aerosol infection of mice with Mtb, activated antigen
specific T cells are not detected in the mediastinal lymph nodes until
9 daysand inthe lungs until 14 dayspost infection. Duringthis early
phase of infection the mycobacterial load increases logarithmically,
but after the first few weeks the primary response to mycobacteria
partially contains mycobacterial growth, so that the mycobacterial
load stabilizes and increases much more slowly or not at all [18,19].
Remarkably, parenteral immunization with BCG, Mtb or subunit
vaccinesonlyslightlyacceleratesthe immuneresponse,sothat when
mice are challenged with Mtb the kinetics of pulmonary Mtb growth
do not differ between naı ¨ve and immune mice for the first 14 days
[2,20,21], although after the initial phase of logarithmic growth the
mycobacterial load stabilizes at a lower level than in naı ¨ve mice.
Thus it appears that systemic immunity only begins to inhibit Mtb
growth relatively late after pulmonary infection. In contrast,
protective immunity following intranasal (i.n.) immunization of
mice with a rec adenovirus expressing Mtb antigen 85A (Ad85A)
induces a large pulmonary population of activated, dividing CD8
effector T cells, many of which can be recovered by broncho-
alveolar lavage (BAL) [2,22]. Mtb growth in Ad85A i.n. immunized
mice is inhibited during the first week after infection but the
mycobacteria then grow logarithmically before the mycobacterial
load again stabilizes at a lower level than in naı ¨ve mice [2].
Stabilization may be due both to a primary response to
mycobacterial antigens absent from the vaccine, as well as
recruitment of cells induced in the systemic immune compartment
by i.n. immunization. Nevertheless, these data suggest that
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27477combining i.n. and parenteral immunization might be effective
because i.n.immunizationgeneratesa pulmonaryimmune response
that can inhibit Mtb growth early after infection, while parenteral
immunity can further inhibit growth later. If this is the case,
simultaneous immunization (SIM) with pulmonary and parenteral
vaccines might be as effective as priming and boosting by these two
routes and would have the advantage of requiring only one
simultaneous immunization procedure. In this study we set out to
test whether SIM by the parenteral and intranasal routes in mice
would provide improved protection over the ‘‘gold standard’’
immunization procedure of parenteral BCG. Here we report that
SIM, which harnesses both local pulmonary and systemic
immunity, induces much more powerful protective immunity than
BCG alone and indeed does not depend on priming and boosting.
Methods
Ethics
All animal work was carried out in accordance with the UK
Animal (Scientific Procedures) Act 1986 and was approved by the
animal use ethical committee of Oxford University.
Animals and Immunization
All experiments were performed with 6–8 week old female
C57BL/6 mice (Harlan Orlac, Blackthorn, UK). Mice were
immunized with 2610
5 colony forming units (cfu) BCG (SSI,
Copenhagen, Denmark) s.c. on the flank in 200 ml PBS. For i.n.
immunization, mice were anesthetized with isoflurane and
2610
5 cfu BCG in 40 ml PBS was administered with a pipette,
divided between the two nostrils. For SIM with BCG 1610
5 cfu
were administered s.c. and 1610
5 cfu i.n. Mice were also
immunized with 4 mg rec antigen 85A protein (85A), prepared
as described previously [23], 20 mg of a synthetic peptide encoding
the first 20 amino acids of the 6 kDa early secreted antigenic target
(E6) (Peptide Protein Research Ltd, Fareham, UK), 4 mg rec
antigen TB10.4 (Proteix, Prague, Czech Republic) or 4 mg of the
enduring hypoxia response protein Rv1284 [24]. Rv1284 was sub-
cloned into the expression vector pET104-DEST42 (Invitrogen,
Paisley, UK) from a complete Gateway Clone set from Mtb
obtained through NIAID’s Pathogen Functional Genomics
Resource Center, managed and funded by Division of Microbi-
ology and Infectious Diseases, NIAID, NIH, DHHS and operated
by the J. Craig Venter Institute. After expression in BL21(DE3) E.
coli cells (Invitrogen) as a His-tagged protein it was purified using
His SpinTrap columns (GE Healthcare, Chalfont St Giles, UK).
Subcutaneous (s.c.) immunization was performed by injecting each
of the antigens, half subcutaneously and half intra-muscularly in
200 ml monophosphoryl lipid A Sigma adjuvant system (MPL)
(Sigma, Poole, UK) prepared according to the manufacturer’s
instructions. For i.n. protein immunization, mice were anesthe-
tized with isoflurane and the same doses of the antigens mixed
with 2 mg of cholera toxin (CT) (Sigma) were pipetted into the
nostrils in a total volume of 40 ml. In most experiments, proteins
were administered 3 times at 2 weekly intervals as indicated in the
figure legends. Mice were also immunized once at the same time
with BCG s.c. and either 4 mg 85A, 20 mgE 6o r4mg TB10.4. The
subunit vaccine was administered either s.c. with MPL or i.n. with
CT as described above. Three types of experiment were
performed. 1) BCG was administered s.c. alone or administered
simultaneously with a recombinant protein or synthetic peptide
antigen s.c. with MPL or i.n. with CT. The mice were challenged
10 weeks later with Mtb (see Fig. 1 and 2) Subunit antigens were
administered three times s.c., i.n. or simultaneously, with MPL or
CT as appropriate, by the two routes at two weekly intervals.
Adjuvant only controls were included in some experiments. Six
weeks after the last immunization, the mice were challenged with
Mtb (see Fig. 2 and 3) BCG only was administered without
adjuvant, s.c., i.n. or simultaneously by both routes (Fig. 3). The
mice were challenged 10 weeks later.
Isolation of lung and spleen lymphocytes
Lungs were perfused with PBS, cut into small pieces and
digested with 0.7 mg/ml collagenase type I (Sigma) and 30 mg/ml
DNase I (Sigma) for 45 min at 37uC. Lung fragments were then
crushed through a cell strainer using a 5 ml syringe plunger,
washed, layered over Lympholyte (Cederlane, Ontario, Canada)
and centrifuged at 10006g for 25 min. Interface cells were
collected and washed. Spleens were passed through a cell strainer
using a 5 ml syringe plunger, red blood cells were lysed using RBC
lysis buffer (Qiagen, Crawley, UK) and the cells were washed.
Flow cytometry
Cells were cultured in Hepes buffered RPMI supplemented with
10% heat-inactivated FCS, L-glutamine, penicillin and strepto-
mycin for 6 hours. Cells were stimulated with Mtb purified protein
derivative (PPD) at 10 mg/ml (SSI) for 12 hours, or a pool of 66
15mer peptides overlapping by 10 amino acids and covering the
entire sequence of 85A or E6 20mer (Peptide Protein Research
Ltd) for 6 hours. Each peptide was at a final concentration of
2 mg/ml during the stimulation. After 6 (for PPD) and 2 (for the
peptide pool) hours at 37uC, Golgi Plug (BD Biosciences, Oxford,
UK) was added according to the manufacturer’s instructions
before intracellular cytokine staining.
Cells were washed and incubated with CD16/CD32 monoclo-
nal antibody to block Fc binding. Subsequently the cells were
stained for CD4 (RM4-5), CD8 (53-6.7) (BD Bioscience, Oxford,
UK) IFNc (XMG1.2), IL-2 (JES6-5H4) and TNF (MP6-XT22)
(eBioscience, Hatfield, UK) using the BD Cytofix/Cytoperm kit
according to the manufacturer’s instructions. Cells were fixed with
PBS+1% paraformaldehyde, run on a LSRII (BD Biosciences) and
analyzed using FlowJo software (Tree Star Inc, Ashland, Oregon,
USA). Three or 4 mice from each experimental group were used
for immunological analysis.
Infection with Mtb and determination of mycobacterial
load
Five to 7 mice were anesthetized with isoflurane and infected
i.n. with Mtb (Erdman strain, kindly provided by Dr. Amy Yang,
CBER/FDA) in 40 ml PBS. Lung cfu were enumerated 24 hours
after challenge to determine the number of organisms deposited,
which was of the order of ,200 cfu. Mice were sacrificed at
indicated times, the lungs were homogenized and the lung
mycobacterial load determined by plating 10-fold serial dilutions
of tissue homogenates on Middlebrook 7H11 agar plates (E&O
Laboratories Ltd, Bonnybridge, UK). Colonies were counted after
3–4 weeks of incubation at 37uCi n5 %C O 2.
Statistical Analysis
All results are representative of at least 2 independent
experiments with similar results. Data were analyzed using one-
way ANOVA followed by Tukey’s multiple comparison test.
Results
SIM with BCG and subunit vaccines
We first tested the efficacy of SIM by administering BCG
subcutaneously (s.c.) and recombinant Mtb antigen 85A protein
SIM against TB
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this experiment 85A with CT was given only once at the same
time as BCG s.c. so that conventional priming and boosting was
not possible. SIM animals were compared to naive or BCG s.c.
controls or mice given both BCG and 85A s.c. with mono-
phosporyl lipid A (MPL) as adjuvant (Fig. 1a). As expected, BCG
s.c. suppressed Mtb growth by 0.8 log10 compared to naive
animals. However, SIM with BCG s.c./85A i.n., targeting both
pulmonary and systemic immunity, provided strikingly increased
protection, reducing Mtb colony forming units (cfu) by an
additional 1.3 log10 compared to BCG s.c. alone. BCG s.c./85A
s.c., targeting only systemic immunity, did not differ from BCG
alone (Fig. 1a). To confirm the generality of this effect we carried
out SIM with two other Mtb antigens, a synthetic peptide encoding
the first 20 amino acids from the 6 kDa early secretory antigenic
target ESAT6 (E6) and rec protein TB10.4. Both BCG s.c./E6 i.n.
Figure 1. Mtb cfu after SIM with BCG and subunit vaccines. a. C57BL/6 mice were immunized once with BCG with or without simultaneous
administration of 85A s.c. or 85A i.n., or b, once with BCG with or without simultaneous administration of E6 s.c. or E6 i.n. and c, once with BCG with
or without simultaneous administration of 10.4 s.c. or 10.4 i.n.. Ten weeks after the last immunization they were challenged with Mtb i.n. and a further
5 weeks sacrificed later for enumeration of lung Mtb cfu. Representative data from one of two experiments with 5–7 mice/group are shown.
***p,0.001, **p,0.01, * p,0.05 between the indicated groups, one-way ANOVA with Tukey’s post test. Data are means 6 s.e.m.
doi:10.1371/journal.pone.0027477.g001
SIM against TB
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pulmonary Mtb load (by 0.6 log10) compared to BCG alone), while
BCG s.c./E6 s.c. and BCG s.c./10.4 s.c. did not (Figs. 1b and c).
SIM with two subunit vaccines
Since SIM with BCG s.c./E6 i.n. provided additional protection
over BCG s.c. alone and BCG does not contain E6, this
experiment strongly suggested that SIM does not require priming
and boosting. To establish this more definitively, we used two non
cross-reactive antigens, 85A and E6. Since adjuvanted rec protein
vaccines are generally administered repeatedly [9,10], we gave the
2 subunit vaccines together or separately with appropriate
adjuvants by the parenteral or pulmonary routes three times at
2 weekly intervals. The mice were challenged with Mtb 6 weeks
after the last immunization (Fig. 2a). SIM with 85A and E6,
targeting pulmonary and systemic immunity, decreased the
mycobacterial load by 1.6 log10 compared to naı ¨ve mice.
Immunization with one antigen by either the pulmonary or
parenteral route alone had a lesser effect (Fig. 2a) and when both
antigens were given together either s.c. or i.n., there was no
significant increase compared to one subunit alone (Fig. 2b and c).
In one experiment (not shown), both 85A i.n./E6 s.c. (as in 2A)
and 85A i.n./E6 i.n. (as in 2C) were included. In this experiment,
there was no significant difference between these two groups but
only the SIM group (85A i.n./E6 s.c.) differed significantly from
the single antigen controls, implying that SIM is more effective
than two antigens i.n.
These subunit vaccine experiments show that the increased
protection of SIM is not due to a prime boost effect. However,
because adjuvant effects are important in immunity to Mtb
[12,25], we also immunized mice 3 times with 85A i.n.+CT, 85A
s.c.+MPL or with CT i.n., MPL s.c. or both simultaneously
(Fig. 2d). The mycobacterial burden in the adjuvant controls did
not differ from naı ¨ve animals even when calculated by T test
(naı ¨ve v CT p=0.33, naı ¨ve v MPL p=0.41 and naı ¨ve v CT/
MPL p=0.29), although 85A given i.n. or s.c. with appropriate
adjuvants provided significant protection. Additionally we
immunized mice 3 times with the hypoxia induced rec protein
Rv1284 [24] s.c. or i.n. with CT or MPL. Rv1284 immunized
mice (Fig. 2e) did not differ from naive animals, indicating that
the efficacy of SIM is dependent on induction of antigen specific
immune responses in the lungs and systemically. This result
provided further evidence for the lack of effect of CT or MPL
without an effective antigen. We hypothesize that Rv1284 may be
ineffective in C57Bl/6 mice because it lacks H-2
b r e s t r i c t e dTc e l l
epitopes.
Figure 3. Mtb cfu after SIM with BCG. a and b. In two experiments, C57BL/6 mice were immunized once with BCG s.c. or BCG i.n. or
simultaneously with the same dose of BCG divided between the s.c./i.n. routes. Ten weeks later they were challenged with Mtb and lung cfu
enumerated 5 weeks later. Data from the two experiments with 5–7 mice/group are shown. ***p,0.001, **p,0.01, * p,0.05 between the indicated
groups, one-way ANOVA with Tukey’s post test. Data are means 6 s.e.m.
doi:10.1371/journal.pone.0027477.g003
Figure 2. Mtb cfu after SIM with subunit vaccines. a. C57BL/6 mice were immunized 3 times at 2 weekly intervals with 85A s.c., or E6 i.n. either
alone or in combination with appropriate adjuvants. Six weeks after the last immunization mice were challenged with Mtb and sacrificed for lung cfu
enumeration 5 weeks later. b. Mice were immunized 3 times with 85A s.c. or E6 s.c. with MPL, separately or in combination and then challenged. c,
the same antigens were administered 3 times i.n. with CT before challenge. d. Mice were immunized with 85A i.n. or s.c. in appropriate adjuvants or
MPL or CT were administered 3 times s.c. or i.n separately or simultaneously and e, Rv1284 was administered s.c. or i.n. 3 times with appropriate
adjuvants before Mtb challenge and enumeration as in a. Representative data from one of two experiments with 5–7 mice/group are shown.
***p,0.001, **p,0.01, * p,0.05 between the indicated groups, one-way ANOVA with Tukey’s post test. Data are means 6 s.e.m.
doi:10.1371/journal.pone.0027477.g002
SIM against TB
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Finally, since BCG is the gold standard vaccine for animal
experiments and the only available human tuberculosis vaccine, we
tested SIM with BCG s.c./BCG i.n. This combination was highly
effective, reducing the mycobacterial load in two separate experiments
by an additional 1.1 and 2.0 log10 compared to BCG given by either
route alone (1.7 and 3.1 log10 compared to naı ¨ve mice) (Fig. 3a and b).
Mechanism of SIM induced additive protection
To investigate the mechanisms underlying the efficacy of SIM,
we assayed antigen specific responses in the lungs and spleen at the
time of Mtb challenge by intra-cytoplasmic cytokine staining (ICS)
and flow cytometry [2,5] for the experiments shown in Figs. 1a,
2a,b,c and 3b. We also analyzed numbers of single or multiple
cytokine producing cells in lungs and spleens (data not shown) [5].
In the experiment shown in Figs. 1a and 4a, in which mice were
immunized only once with BCG and rec 85A, the responses to 85A
in the lungs were low and similar in all groups at 10 weeks post-
immunization (Fig. 4a) although the mice immunised with BCG
s.c./85A i.n. were very well protected (Fig. 1a). In the experiments
shown in Figs. 2a,b,c and 4b, or 3b and 4c, lung responses were
higher in i.n. or simultaneously immunized mice. In all experiments
the percentages of antigen specific cells in the spleen were lower
than in the lungs and overall there were no consistent differences
between mice immunized s.c., i.n. or simultaneously. Therefore in
these experiments protection did not correlate clearly with the
number of antigen specific cells in the lungs or spleen.
Although we could not discern a definitive correlation between
the number and quality of antigen specific cells and protective
immunity and both immunization routes induced splenic respons-
es of approximately equal magnitude (Fig. 4), the fact that i.n. but
not s.c. immunization always induced populations of antigen
specific cells in the lungs, suggested that these may be important
for the success of SIM. We therefore turned to in vivo analysis of
immune function to determine the effect of i.n. or SIM
immunization and examined the kinetics of Mtb growth after
challenge in mice given antigen i.n., s.c. or simultaneously by both
routes. All i.n. vaccines that provide additional protection when
given simultaneously with parenteral vaccines, inhibited Mtb
growth by 7 days post-challenge and inhibition compared to
naı ¨ve mice was also seen at later time points. In contrast, effective
parenteral vaccines, including BCG, did not inhibit growth at 7
days but began to do so at 14 days and continued to inhibit at later
time points. When the kinetics of mycobacterial growth were
examined in SIM mice, both early and additional later inhibition
were seen. Figures 5 and 6 show the data from these experiments,
either as the kinetics of growth (Fig. 5) or as growth inhibition for
individual mice at each time point (Fig. 6).
Discussion
A distinctive feature of pulmonary infection of mice with Mtb is
the delay in initiation of a primary immune response in the
draining mediastinal lymph nodes, so that Mtb grows logarithmi-
cally in the lungs during the early phase of infection [18,19,26].
Only after the primary response generates effectors that recirculate
to the lung does the mycobacterial load stabilize. Even after
parenteral immunization with an effective vaccine, BCG, the
kinetics of mycobacterial growth are not changed during the first 7
days after challenge, although the mycobacterial load later
stabilizes at a lower level than in naı ¨ve mice [2]. In contrast, in
mice immunized i.n. early Mtb growth is inhibited, as well as
stabilizing at a lower level than in naı ¨ve mice [2]. Intranasal
vaccines are often more effective than parenteral immunization
against Mtb [5,13,14,17] perhaps because i.n. vaccines induce
pulmonary immunity that inhibits early mycobacterial growth,
while the primary response to non-vaccine antigens may
contribute to the later stabilization of mycobacterial load. In any
case, we hypothesize that i.n. and parenteral immunization are
additive because i.n. immunization induces a pulmonary immune
response that inhibits mycobacterial growth early after challenge,
while systemic immunity induced by parenteral immunization
inhibits mycobacterial growth only later. Because parenteral and
pulmonary immunization induce populations of immune cells with
differing localization and effects on mycobacterial growth kinetics,
we reasoned that their additive effect might not depend on a
prime/boost effect and that simultaneous immunization (SIM)
should be effective.
The data shown here confirm that BCG s.c. combined with one
of three i.n. subunit vaccines, rec 85A, rec TB10.4 or E6 peptide
provides increased protection compared to BCG alone. All of the
i.n. subunit vaccines or i.n. BCG, inhibit early growth of
mycobacteria in the lungs (Figs. 5 and 6). Furthermore, SIM is
effective with two non-crossreacting vaccines, rec 85A adminis-
tered i.n. with cholera toxin as a mucosal adjuvant and ESAT61–20
peptide given parenterally with monophosphoryl lipid A as
adjuvant. These experiments demonstrate that prime/boosting is
not needed to obtain the additive effect of SIM. Interestingly SIM
with BCG s.c./BCG i.n. is also highly effective, a result that
contrasts with the finding that boosting BCG primed animals with
BCG is generally ineffective. SIM with BCG may be effective not
only because it induces early and late inhibition of Mtb growth
after challenge (Figs. 5 and 6), but also because it circumvents the
problem of inhibition of growth of booster BCG in BCG primed
animals.
Although inhibition of early and later growth of Mtb clearly
contribute to the efficacy of SIM, the immune mechanisms require
further investigation. Even parenterally administered BCG has
been shown to induce changes in expression of lung genes involved
in connective tissue responses that last for at least 6 weeks [25] and
are important in the host response to Mtb [27]. These changes may
contribute to the efficacy of SIM when BCG is given s.c. with a
second antigen i.n. Furthermore, although we have not seen
protective effects of CT and MPL when used without antigens or
with Rv1284, the effects of these adjuvants on lung gene
expression have not been investigated and may contribute to
Figure 4. Cytokine responses of lung and spleen T cells to antigens. a. Mice were immunized with BCG s.c., BCG s.c./85A s.c. or BCG s.c./85A
i.n. as in Fig. 1a. Lung and spleen cells were isolated 10 weeks after immunization and stimulated with pooled 85A peptides for 6 hours. b. mice were
immunized 3 times at 2 weekly intervals with 85A s.c., 85A i.n., E6 s.c. or E6 i.n. either alone or in combination as in Fig. 2a,b,c and cells isolated 6
weeks after immunization and stimulated with pooled 85A peptides or E6 for 6 hours. c, mice were immunized with BCG s.c., BCG i.n. or BCG s.c./i.n.
as in Fig. 3b and lung cells were isolated 10 weeks after immunization and stimulated for 12 hours with PPD. After stimulation the proportion of IFNc,
IL-2 and TNF producing cells was determined by flow cytometry of CD4 gated cells (numbers of responding CD8 cells were too low for reliable
analysis). Results are expressed as the means 6 s.e.m. of 3 or 4 mice per group and are representative of 2 independent experiments. In a,
***p,0.001, **p,0.01 indicate significant differences between numbers of spleen IL-2 producing cells only. In b,**p,0.01 between all cytokines in
the indicated groups and in c, **p,0.01 for TNF only. All other groups differ significantly from the naı ¨ve group but these comparisons are omitted for
simplicity. One-way ANOVA with Tukey’s post test.
doi:10.1371/journal.pone.0027477.g004
SIM against TB
PLoS ONE | www.plosone.org 7 November 2011 | Volume 6 | Issue 11 | e27477Figure 5. Kinetics of Mtb growth after s.c. and i.n. immunization. C57BL/6 mice were immunized once with BCG s.c., BCG i.n. or BCG s.c./BCG
i.n. or 3 times at two weekly intervals with 85A s.c., 85A i.n., E6 s.c. or E6 i.n. Ten weeks after immunization with BCG or 4 weeks after the last
immunization with 85A or E6, mice were challenged with Mtb and groups of 3–5 mice sacrificed 7, 14, 21 and 28 days later for enumeration of lung
Mtb cfu. # indicates a significant difference between s.c immunized and naı ¨ve mice and * a significant difference between i.n. or SIM immunized
mice and naı ¨ve controls, one-way ANOVA with Tukey’s post test. Data are means 6 s.e.m. Standard errors are small, so that the error bars are within
the symbols when not visible.
doi:10.1371/journal.pone.0027477.g005
SIM against TB
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protective effects of BCG against virulent mycobacteria may be
lost with time after challenge [28], so that it will be very important
in future investigation of SIM, to study both the duration of
protective immunity after immunization and the long term
maintenance of protection post challenge.
While effects on innate and connective tissue responses may be
important for protective immunity to Mtb, the adaptive response is
clearly also important. Both CD8 T cells induced by Ad85A i.n.
[2] or CD4 T cells as shown here and elsewhere [29], can mediate
early inhibition of mycobacterial growth. It is also clear that their
location within the lung is crucial since although significant
numbers of antigen specific cells may sometimes be present in the
lungs after parenteral immunization [29,30], these are found in the
lung interstitium, while in contrast i.n. immunization establishes a
long-lived population of lung resident, activated, antigen-specific T
cells, recoverable by BAL [2,22,29]. The BAL population
expresses CXCR6 and is highly protective [22,29]. In the present
experiments we did not see a clear correlation between the
numbers of antigen-specific cells in the lungs and protective
Figure 6. Mtb growth in individual mice after s.c. and i.n. immunization. The figure shows results for individual mice from the experiments
shown in Fig. 5. C57BL/6 mice were immunized once with BCG s.c., BCG i.n. or BCG s.c./BCG i.n. or 3 times at two weekly intervals with 85A s.c., 85A
i.n., E6 s.c. or E6 i.n. Ten weeks after immunization with BCG or 4 weeks after the last immunization with 85A or E6 mice were challenged with Mtb
and groups of 3–5 mice sacrificed 7, 14, 21 and 28 days later for enumeration of lung Mtb cfu. Representative data from one of two experiments are
shown. Horizontal lines show group means. # indicates a significant difference from naı ¨ve mice and * a significant difference between indicated
groups. One-way ANOVA with Tukey’s post test.
doi:10.1371/journal.pone.0027477.g006
SIM against TB
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sion on lung lymphocytes, nor did we separate BAL and interstitial
lymphocytes. The lack of an observed correlation may therefore
indicate that the location within the lung and state of activation of
lymphocytes, are more critical than the overall numbers. In future
studies of i.n. immunized or SIM mice, it will be important to
dissect responses in different lung compartments before drawing
conclusions as to the hallmarks of protective i.n. or SIM induced
immunity.
SIM with BCG s.c./BCG i.n. is highly effective and sets a new
gold standard against which to measure Mtb vaccine efficacy
(Fig. 3). Another SIM regime, BCG s.c./85A i.n., is highly
effective (Fig. 1a) but clearly there are many possibilities for
improvement of SIM with subunits, such as the use of multiple
antigens (including latency antigens) as fusion genes [11], or
recombinant mycobacteria over-expressing immunogenic antigens
[1,31]. Adjuvants and vectors for pulmonary delivery also need to
be further developed. SIM has several potential advantages: first, it
is highly effective and rapidly establishes a much higher level of
protection than BCG alone; second, it only requires immunization
procedures that might be performed at a single clinic visit; third, it
is compatible with further boosting with subunit vaccines or the
employment of recombinant mycobacteria. Some of the latter are
as effective as BCG in inducing protective immunity but may be
less pathogenic, an important property in HIV+ immuno-
compromised individuals [32]. The long-term efficacy, practicality
and safety of pulmonary vaccines remain to be thoroughly
investigated. However, BCG, rec adenoviruses and rec proteins
with adjuvants have all been shown to induce long lasting
protection [2,12]. Cheap, disposable devices to administer spray
dried particles or nebulised aerosols for pulmonary vaccination
have been developed [33,34], while respiratory immunization
against measles has been shown to be safe and highly efficient.
Nebulised BCG has been safely administered to the lungs of .100
children and young adults with no reported ill effects [35].
SIM harnessing both local and systemic immunity is a novel
strategy for immunization against Mtb, complementary to current
parenteral prime boost regimes and with the potential to enhance
greatly the efficacy of existing promising subunit vaccines. SIM
merits further investigation and development.
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